Zucara Therapeutics, Inc.

TRex Bio Inc. (TRexBio) announced an $84m series B venture capital round on 13 November that it will use to develop lead drug candidate TRB-061, a TNFR2 agonist, through early clinical proof-of-concep

Stock market volatility due to business interruptions caused by the novel coronavirus has brought most fundraising by public companies to a halt, but so far COVID-19 hasn’t slowed the flow of venture

A prolific partner for industry tapping into academic research, Johns Hopkins University has benefited from having a coordinated structure for deal-making that offers incubation and mentoring for